<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03060577</url>
  </required_header>
  <id_info>
    <org_study_id>MDCO-PCS-16-01</org_study_id>
    <nct_id>NCT03060577</nct_id>
  </id_info>
  <brief_title>An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol</brief_title>
  <acronym>ORION-3</acronym>
  <official_title>An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ORION-3 is a Phase II, open-label, non-randomized, active comparator extension trial to&#xD;
      assess the efficacy, safety, and tolerability of long-term dosing of inclisiran and&#xD;
      evolocumab given as subcutaneous injections in participants with high cardiovascular risk and&#xD;
      elevated low-density lipoprotein cholesterol (LDL-C).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ORION-3 is an open label, long term extension study with two arms: Group 1 (inclisiran only&#xD;
      arm) will receive inclisiran only and Group 2 (switching arm) will receive an active&#xD;
      comparator (evolocumab) followed by inclisiran.&#xD;
&#xD;
      ORION-3 will be conducted in subjects with atherosclerotic cardiovascular disease (ASCVD) or&#xD;
      ASCVD-risk equivalents (eg, diabetes and familial hypercholesterolemia) and elevated LDL-C&#xD;
      despite maximum tolerated dose of LDL-C lowering therapies who have completed study&#xD;
      MDCO-PCS-15-01 (ORION-1) [NCT02597127], to evaluate the efficacy, safety, and tolerability of&#xD;
      long-term dosing of inclisiran.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 24, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in LDL-C at Day 210 Compared to Day 1 of the ORION_1 Study (Inclisiran Arm)</measure>
    <time_frame>Day 1, Day 210</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in LDL-C</measure>
    <time_frame>Day 1, Day 210 and Day 1440 (or Final Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in LDL-C</measure>
    <time_frame>Day 1, Day 210 and Day 1440 (or Final Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in PCSK9 Levels</measure>
    <time_frame>Day 1, Day 210 and Day 1440 (or Final Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in PCSK9 Levels</measure>
    <time_frame>Day 1, Day 210 and Day 1440 (or Final Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in Total Cholesterol, Triglycerides, HDL-C, non-HDL-C, VLDL-C, Apo-A1, Apo-B, and Lp(a)</measure>
    <time_frame>Day 1, Day 210 and Day 1440 (or Final Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Participants in the Inclisiran Group from Day 1 to Day 210 and to Day 1440 (or Final Visit) in Total Cholesterol, Triglycerides, HDL-C, non-HDL-C, VLDL-C, Apo-A1, Apo-B, and Lp(a)</measure>
    <time_frame>Day 1, Day 210 and Day 1440 (or Final Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants in the Inclisiran Group and the Evolocumab Group Who Attain Global Lipid Modification Targets for Their Level of ASCVD Risk</measure>
    <time_frame>Day 210 and Day 1440 (or Final Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants in the Evolocumab Group Who Attain Global Lipid Modification Targets for Their Level of ASCVD Risk at Day 570 (210 Days After Starting Inclisiran)</measure>
    <time_frame>Day 570</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants in the Inclisiran Group and the Evolocumab Group with â‰¥50% LDL-C Reduction</measure>
    <time_frame>Day 210 and Day 570</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in the Inclisiran Group and the Evolocumab Group Reaching on Treatment LDL-C Levels of &lt;25 mg/dL, &lt;50 mg/dL, &lt;70 mg/dL, and &lt;100 mg/dL</measure>
    <time_frame>Day 210 and Day 570</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Lipid Lowering Effect in Participants in the Inclisiran Group and the Evolocumab Group</measure>
    <time_frame>Day 1 through Day 1440</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day 1 to Day 360 in LDL-C (Beta Quantification) of Participants in the Evolocumab Group</measure>
    <time_frame>Day 1, Day 360</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day 30 to Day 360 in Participant-Reported Scores Using the Treatment Satisfaction Questionnaire for Medication (TSQM) Questionnaire of Participants in the Inclisiran Group and the Evolocumab Group</measure>
    <time_frame>Day 30, Day 360</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day 450 to Day 720 in Participant-Reported Scores Using the TSQM Questionnaire of Participants in the Inclisiran Group</measure>
    <time_frame>Day 450, Day 720</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant-Reported Adherence to Self-Injectable Evolocumab</measure>
    <time_frame>Day 30 through Day 360</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">490</enrollment>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <condition>Symptomatic Atherosclerosis</condition>
  <condition>Type2 Diabetes</condition>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Inclisiran-only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneous injections of inclisiran 300 milligrams (mg) on Day 1 and every 180 days thereafter for up to 4 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Switching</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive self-administered subcutaneous injections of evolocumab 140 mg on Day 1 and every 14 days thereafter until Day 336. Then, the participants will receive subcutaneous injections of inclisiran 300 mg on Day 360 and every 180 days thereafter for up to 4 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inclisiran</intervention_name>
    <description>Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.</description>
    <arm_group_label>Inclisiran-only</arm_group_label>
    <arm_group_label>Switching</arm_group_label>
    <other_name>ALN-PCSSC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.</description>
    <arm_group_label>Switching</arm_group_label>
    <other_name>REPATHA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Completion of Study MDCO-PCS-15-01 and no contraindication to receiving inclisiran or&#xD;
             evolocumab.&#xD;
&#xD;
          2. Willing and able to give written and informed consent before initiation of any study&#xD;
             related procedures and willing to comply with all required study procedures.&#xD;
&#xD;
          3. Willing to self-inject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any uncontrolled or serious disease, or any medical or surgical condition that may&#xD;
             either interfere with participation in the clinical study and/or put the participant&#xD;
             at significant risk (according to investigator's [or delegate's] judgment).&#xD;
&#xD;
          2. An underlying known disease or surgical, physical, or medical condition that, in the&#xD;
             opinion of the investigator (or delegate), might interfere with interpretation of the&#xD;
             clinical study results.&#xD;
&#xD;
          3. Serious comorbid disease in which the life expectancy of the participant is shorter&#xD;
             than the duration of the trial (for example, acute systemic infection, cancer, or&#xD;
             other serious illnesses).&#xD;
&#xD;
          4. Active liver disease defined as any known current infectious, neoplastic, or metabolic&#xD;
             pathology of the liver; unexplained alanine aminotransferase (ALT) or aspartate&#xD;
             aminotransferase (AST) elevation greater than 2 times upper limit of normal (ULN); or&#xD;
             total bilirubin elevation greater than 1.5 times ULN at study entry visit.&#xD;
&#xD;
          5. Females who are pregnant or nursing, or who are of childbearing potential and&#xD;
             unwilling to use at least two methods of contraception (for example, oral&#xD;
             contraceptives, barrier methods, approved contraceptive implant, long-term injectable&#xD;
             contraception, intrauterine device) for the entire duration of the study. Exemptions&#xD;
             from this criterion are&#xD;
&#xD;
               -  Women &gt;2 years postmenopausal (defined as 1 year or longer since their last&#xD;
                  menstrual period) AND more than 55 years of age&#xD;
&#xD;
               -  Postmenopausal women (as defined above) and less than 55 years old with a&#xD;
                  negative pregnancy test within 24 hours of enrollment&#xD;
&#xD;
               -  Women who are surgically sterilized at least 3 months prior to enrollment&#xD;
&#xD;
          6. Males who are unwilling to use an acceptable method of birth control during the entire&#xD;
             study period (that is, condom with spermicide).&#xD;
&#xD;
          7. Treatment with investigational medicinal products other than inclisiran or devices&#xD;
             within 30 days or five halfË—lives, whichever is longer.&#xD;
&#xD;
          8. Planned use of investigational medicinal products other than inclisiran or devices&#xD;
             during the course of the study.&#xD;
&#xD;
          9. Participants with a history of a serious hypersensitivity reaction to evolocumab or&#xD;
             any of the excipients&#xD;
&#xD;
         10. Previous or current treatment (within 90 days of study entry) with monoclonal&#xD;
             antibodies directed towards PCSK9.&#xD;
&#xD;
         11. Any condition that according to the investigator could interfere with the conduct of&#xD;
             the study, such as but not limited to:&#xD;
&#xD;
               -  Inappropriate for this study, including participants who are unable to&#xD;
                  communicate or to cooperate with the investigator.&#xD;
&#xD;
               -  Unable to understand the protocol requirements, instructions and study-related&#xD;
                  restrictions, the nature, scope, and possible consequences of the study&#xD;
                  (including participants whose cooperation is doubtful due to drug abuse or&#xD;
                  alcohol dependency).&#xD;
&#xD;
               -  Unlikely to comply with the protocol requirements, instructions, and&#xD;
                  study-related restrictions (for example, uncooperative attitude, inability to&#xD;
                  return for follow-up visits, and improbability of completing the study).&#xD;
&#xD;
               -  Involved with, or a relative of, someone directly involved in the conduct of the&#xD;
                  study.&#xD;
&#xD;
               -  Any known cognitive impairment (for example, Alzheimer's Disease).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kausik Ray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute For Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Icahn School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic And Atherosclerosis Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont CVA Heart Institute</name>
      <address>
        <city>Greeneville</city>
        <state>Tennessee</state>
        <zip>37745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amarillo Heart Clinical Research Institute, Inc.</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research, Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Boniface Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Regional Health Authority, Patient Research Centre</name>
      <address>
        <city>Saint John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brampton Research Associates</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6Z 4N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawson Health Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ECOGENE-21 Clinical Trials Center</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Recherches Cliniques de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre intÃ©grÃ© universitaire de santÃ© et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ© Laval Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des maladies lipidique Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Essen</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Hospital Heidelberg, Internal Medicine III</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technical University Munich, German Heart Center</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga Hospital</name>
      <address>
        <city>Den Haag</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Eindoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>5611 NV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Admiraal de Ruyter Hospital, Cardiology</name>
      <address>
        <city>Goes</city>
        <zip>4462 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda Diabetes Research Center</name>
      <address>
        <city>Hoogeveen</city>
        <zip>7909 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Gorecht</name>
      <address>
        <city>Hoogezand</city>
        <zip>9603 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VOC Hoorn</name>
      <address>
        <city>Hoorn</city>
        <zip>1624 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum (LUMC)</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andromed Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <zip>3039 BD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonesseshuis, Vascular Policlinic</name>
      <address>
        <city>Utrecht</city>
        <zip>3582 KE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VieCurie Venlo, Cardiology</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Hospital, Cardiology</name>
      <address>
        <city>Zwijndrecht</city>
        <zip>3331 LZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Royal Infirmary</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Devon and Exeter NHS Trust</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fowey River Practice</name>
      <address>
        <city>Fowey</city>
        <zip>PL23 1DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buckinghamshire NHS Trust</name>
      <address>
        <city>High Wycombe</city>
        <zip>HP11 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oak Tree Surgery</name>
      <address>
        <city>Liskeard</city>
        <zip>PL14 3XA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester University Hospital NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alverton Practice</name>
      <address>
        <city>Penzance</city>
        <zip>TR18 4JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knowle House Surgery</name>
      <address>
        <city>Plymouth</city>
        <zip>PL5 3JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brannel Surgery</name>
      <address>
        <city>Saint Austell</city>
        <zip>PL26 7RL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rame Medical Ltd (Rame Research)</name>
      <address>
        <city>Torpoint</city>
        <zip>PL11 2TB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worcestershire Acute NHS Trust</name>
      <address>
        <city>Worcester</city>
        <zip>WR5 1DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 17, 2017</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

